Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.